QA102 Phase II Study in Subjects With Dry AMD - Trial NCT05536752
Access comprehensive clinical trial information for NCT05536752 through Pure Global AI's free database. This Phase 2 trial is sponsored by Smilebiotek Zhuhai Limited and is currently Recruiting. The study focuses on Dry Age-related Macular Degeneration. Target enrollment is 240 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Smilebiotek Zhuhai Limited
Timeline & Enrollment
Phase 2
Sep 22, 2022
Oct 01, 2025
Primary Outcome
proportion of subjects with disease progression to CNV or significant GA change as defined in the protocol
Summary
This is a phase 2, double-masked, randomized, placebo-controlled, dose-response study. The
 primary objective of the study is to evaluate the efficacy of QA102 oral capsules on the
 development of GA or CNV in high-risk eyes.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05536752
Non-Device Trial